Last reviewed · How we verify
Phase C: Eplerenone
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss. Used for Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction, Hypertension.
At a glance
| Generic name | Phase C: Eplerenone |
|---|---|
| Also known as | Eplerenone |
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Drug class | Selective aldosterone antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and decreased cardiac fibrosis and remodeling. Unlike non-selective aldosterone antagonists, eplerenone has minimal affinity for other steroid receptors, reducing hormonal side effects.
Approved indications
- Heart failure with reduced ejection fraction
- Post-myocardial infarction left ventricular dysfunction
- Hypertension
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase C: Eplerenone CI brief — competitive landscape report
- Phase C: Eplerenone updates RSS · CI watch RSS
- National Institute of Cardiology, Warsaw, Poland portfolio CI